IDXXIDXX
US • —
$526.44
P/E
38.73
PEG
1.51
FCF Yield
—
Rev Growth YoY
+13.1% YoY
Gross Margin
62.0%
Health Score
8/10
D/E Ratio
0.53
Confidence
LOW
Business Snapshot
IDEXX Laboratories develops diagnostic products and services primarily for the veterinary industry, with its core revenue driver being its reference laboratory and point-of-care diagnostic testing systems for companion animals. The company operates in the global veterinary diagnostics market, where it is the dominant leader with an estimated 30-40% market share, supported by its integrated platform of instruments, consumables, and cloud-based practice management software. Market capitalisation data is unavailable in this dataset; however, the company's TTM revenue is also not provided, limiting the assessment of financial scale from this data alone. A defining characteristic is its deeply entrenched installed base of over 70,000 in-clinic analyzers globally, creating significant switching costs for veterinary practices and a recurring revenue stream from consumables.
Financial Health
IDEXX showcases high profitability with a gross margin of 62.0% and a net margin of 24.6%, reflecting strong pricing power within its niche. The balance sheet is healthy, with a debt-to-equity ratio of 0.53x, indicating manageable leverage, and a current ratio of 1.23x, suggesting sufficient short-term liquidity to cover obligations...
Risk Assessment
- VALUATION — P/E of 38.73x is a significant premium to the sector average of 22x, pricing in high growth expectations.
- EARNINGS QUALITY — While the company is beating estimates, this risk is not evident from the data; the metric for "out of 4 recent quarters beat" is 4/4, which is a positive signal, not a risk. This item is omitted.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- DATA COMPLETENESS — The absence of market cap, TTM revenue, and free cash flow figures limits the ability to fully assess financial scale and cash generation, impacting valuation context....
IDEXX showcases high profitability with a gross margin of 62.0% and a net margin of 24.6%, reflecting strong pricing power within its niche. The balance sheet is healthy, with a debt-to-equity ratio of 0.53x, indicating manageable leverage, and a current ratio of 1.23x, suggesting sufficient short-term liquidity to cover obligations. Free cash flow and FCF yield data are unavailable in this payload, preventing a direct assessment of cash generation efficiency. The combination of robust margins, low leverage, and high returns on equity of 70.9% points to a financially sound company capable of self-funding growth initiatives and reinvesting in its competitive moat.
- VALUATION — P/E of 38.73x is a significant premium to the sector average of 22x, pricing in high growth expectations. - EARNINGS QUALITY — While the company is beating estimates, this risk is not evident from the data; the metric for "out of 4 recent quarters beat" is 4/4, which is a positive signal, not a risk. This item is omitted. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - DATA COMPLETENESS — The absence of market cap, TTM revenue, and free cash flow figures limits the ability to fully assess financial scale and cash generation, impacting valuation context.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives